MARKET

INO

INO

Inovio Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.91
-0.28
-3.05%
After Hours: 9.02 +0.11 +1.23% 19:02 03/08 EST
OPEN
9.20
PREV CLOSE
9.19
HIGH
9.45
LOW
8.88
VOLUME
9.86M
TURNOVER
--
52 WEEK HIGH
33.79
52 WEEK LOW
5.13
MARKET CAP
1.85B
P/E (TTM)
-7.9789
1D
5D
1M
3M
1Y
5Y
Global Polymers Drug Delivery Market Size, Share, Value, and Competitive Landscape 2020-2026
Mar 06, 2021 (Heraldkeepers) -- Global Polymers Drug Delivery Market Report 2020 comes with the extensive industry analysis of development components,...
Heraldkeepers · 2d ago
Inovio Pharmaceuticals Inc. stock rises Friday, still underperforms market
Shares of Inovio Pharmaceuticals Inc. inched 0.44% higher to $9.19 Friday, on what proved to be an all-around favorable trading session for the stock market,...
marketwatch.com · 3d ago
UK DNA Vaccine Market will experience a noticeable growth during the forecast period 2019-2025: Orion Market Reports
Mar 05, 2021 (Market Insight Reports) -- The UK DNA Vaccine market is anticipated to grow at a CAGR 42.9% during the forecast period. The UK is one of the...
Market Insight Reports · 3d ago
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors
Shares of Inovio Pharmaceuticals Inc. shed 4.29% to $9.15 Thursday, on what proved to be an all-around poor trading session for the stock market, with the...
marketwatch.com · 4d ago
INOVIO to Present at Upcoming Investor Conferences in March
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced that Dr. J. Joseph Kim, President and CEO, along with other members...
PR Newswire · 4d ago
Inovio Is Still Working On Finishing A Midstage Covid Vaccine Test Is It A Buy?
Inovio stock is among the many companies targeting a coronavirus vaccine. But INO stock is volatile and has a weak history. Is the biotech stock a safe bet?
Investor's Business Daily · 4d ago
Remdesivir (COVID-19) Market Research Report 2020-2026: By Product, Application, Manufacturer, Sales and Segmentation
Mar 04, 2021 (Market Insight Reports) -- A recent report provides crucial insights along with application based and forecast information in the Global...
Market Insight Reports · 4d ago
Global Needle-free Drug Delivery Devices Market Size, 2021 Industry Share, Global Analysis, Development Status, Regional Trends, Opportunity Assessment and Comprehensive Research Study Till 2023
Mar 04, 2021 (The Expresswire) -- Global "Needle-free Drug Delivery Devices Market" 2021 report discusses the market size, drivers and restraints, segment...
The Express Wire · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of INO. Analyze the recent business situations of Inovio Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average INO stock price target is 16.00 with a high estimate of 35.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 378
Institutional Holdings: 68.02M
% Owned: 32.76%
Shares Outstanding: 207.63M
TypeInstitutionsShares
Increased
71
6.55M
New
93
2.23M
Decreased
53
3.34M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.04%
Pharmaceuticals & Medical Research
-0.50%
Key Executives
Chairman/Independent Director
Simon Benito
Chief Executive Officer/President/Director
Jong Kim
Chief Financial Officer
Peter Kies
Chief Operating Officer
Jacqueline Shea
Chief Operating Officer
Jacqueline Elizabeth Shea
Chief Scientific Officer
Laurent Humeau
Director
David Weiner
Independent Director
Ann Miller
Independent Director
Jay Shepard
Independent Director
Wendy Yarno
Independent Director
Lota Zoth
No Data
About INO
Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Webull offers kinds of Inovio Pharmaceuticals Inc stock information, including NASDAQ:INO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INO stock methods without spending real money on the virtual paper trading platform.